Antisense-mediated melanoma inhibitor of apoptosis protein downregulation sensitizes G361 melanoma cells to cisplatin

Anti-Cancer Drugs

Volumn 17, Issue 9, 2006, Pages 1031-1039

  Mousavi Shafaei, Parisa ^a,c   Ziaee, Abed Ali ^a   Azizi, Ebrahim ^a   Zangemeister Wittke, Uwe ^b  

^a TEHRAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^b UNIVERSITY OF ZURICH   (Switzerland)

^c UNIVERSITY OF TEHRAN   (Iran)

Author keywords

Antisense; Apoptosis; Cisplatin; Melanoma; Melanoma inhibitor of apoptosis protein

Indexed keywords

ANTISENSE OLIGONUCLEOTIDE; CISPLATIN; INHIBITOR OF APOPTOSIS PROTEIN; LIPOCORTIN 5; M 706; MESSENGER RNA; UNCLASSIFIED DRUG;

APOPTOSIS; ARTICLE; CELL DEATH; CELL GROWTH; CELL STRUCTURE; CELL VIABILITY; COLORIMETRY; DOWN REGULATION; HUMAN; HUMAN CELL; IMMUNOBLOTTING; MELANOMA CELL; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; PROTEIN EXPRESSION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; STAINING;

ANTINEOPLASTIC AGENTS; APOPTOSIS; CELL LINE, TUMOR; CELL SURVIVAL; CISPLATIN; DOWN-REGULATION; HUMANS; INHIBITOR OF APOPTOSIS PROTEINS; MELANOMA, EXPERIMENTAL; OLIGONUCLEOTIDES, ANTISENSE; RNA, MESSENGER; RNA, SMALL INTERFERING;

EID: 33749029242     PISSN: 09594973     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.cad.0000231474.77159.e3     Document Type: Article

References (45)

1. Serrone L, Hersey P. The chemoresistance of human malignant melanoma: an update. Melanoma Res 1999; 9:51-58.
2. Grossman D, Altieri DC. Drug resistance in melanoma: mechanisms, apoptosis, and new potential therapeutic targets. Cancer Metastasis Rev 2001; 20:3-11.
3. Helmbach H, Rossmann E, Kern MA, Schadendorf D. Drug-resistance in human melanoma. Int J Cancer 2001; 93:617-622.
4. Middleton MR, Grob J, Asronson N, Fierlbeck G, Tilgen W, Seiter S, et al. Randomized phase III study of temozolomide versus dacarbazine in the treatment of patients with advanced metastatic malignant melanoma. J Clin Oncol 2000; 18:158-166.
5. Becker JC, Kampgen E, Brocker E. Classical chemotherapy for metastatic melanoma. Clin Exp Dermatol 2000; 25:504-508.
6. Jemal A, Thomas A, Murray T, Thun M. Cancer statistics. CA Cancer J Clin 2002; 52:23-47.
7. Susin SA, Zamzami N, Kroemer G. Mitochondria as regulators of apoptosis: doubt no more. Biochim Biophys Acta 1998; 1366:151-165.
8. Chapman PB, Einhorn LH, Meyers ML, Saxman S, Destro AN, Panageas K, et al. Phase III multi-center randomized trial of the Dartmouth regimen versus dacarbazine in patients with metastatic melanoma. J Clin Oncol 1999; 17:2745-2751.
9. Bradbury PA, Middleton MR. DNA repair pathways in drug resistance in melanoma. Anticancer Drugs 2004; 15:421-426.
10. Meyskens FL Jr, Buckmeier JA, McNulty SE, Tohidian NB. Activation of nuclear factor-kappa B in human metastatic melanoma cells and the effect of oxidative stress. Clin Cancer Res 1999; 5:1197-1202.
11. McNulty SE, Tohidian NB, Meyskens FL Jr. RelA, p50 and inhibitor of kappa B alpha are elevated in human metastatic melanoma cells and respond aberrantly to ultraviolet light B. Pigment Cell Res 2001; 14:456-465.
12. Birck A, Ahrenkiel V, Zeuthen J, Hou-Jensen K, Guldberg P. Mutation and allelic loss of the PTEN/MMAC1 gene in primary and metastatic melanoma biopsies. J Invest Dermatol 2000; 114:277-280.
13. Zhou XP, Gimm O, Hampel H, Niemann T, Walker MJ, Eng C. Epigenetic PTEN silencing in malignant melanomas without PTEN mutation. Am J Pathol 2000; 157:1123-1128.
14. Zhai S, Yaar M, Doyle SM, Gilchrest BA. Nerve growth factor rescues pigment cells from ultraviolet-induced apoptosis by upregulating BCL-2 levels. Exp Cell Res 1996; 224:335-343.
15. Ambrosini G, Adida C, Sirugo G, Altieri DC. Induction of apoptosis and inhibition of cell proliferation by survivin gene targeting. J Biol Chem 1998; 273:11177-11182.
16. Grossman D, McNiff JM, Li F, Altieri DC. Expression and targeting of the apoptosis inhibitor, survivin, in human melanoma. J Invest Dermatol 1999; 113:1076-1081.
17. Vucic D, Deshayes K, Ackerly H, Pisabarro MT, Kadkhodayan S, Fairbrother WJ, Dixit VM. SMAC negatively regulates the anti-apoptotic activity of melanoma inhibitor of apoptosis (ML-IAP). J Biol Chem 2002; 277:12275-12279.
18. Kasof GM, Gomes BC. Livin, a novel inhibitor of apoptosis protein family member. J Biol Chem 2001; 276:3238-3246.
19. Deveraux QL, Reed JC. IAP family proteins - suppressors of apoptosis. Genes Dev 1999; 13:239-252.
20. Salvesen GS, Duckett CS. IAP proteins: blocking the road to death's door. Nat Rev Mol Cell Biol 2002; 3:401-410.
21. Lin J-H, Deng G, Huang Q, Morser J. KIAP, a novel member of the inhibitor of apoptosis protein family. Biochem Biophys Res Commun 2000; 279:820-831.
22. Vucic D, Stennicke HR, Pisabarro MT, Salvesen GS, Dixit VM. ML-IAP, a novel inhibitor of apoptosis that is preferentially expressed in human melanomas. Curr Biol 2000; 10:1359-1366.
23. Ashhab Y, Alian A, Polliack A, Panet A, Yehuda DB. Two splicing variants of a new inhibitor of apoptosis gene with different biological properties and tissue distribution pattern. FEBS Lett 2001; 495:56-60.
24. Gong J, Chen N, Zhuo Q, Yang B, Wang Y, Wang X. Melanoma inhibitor of apoptosis protein is expressed differentially in melanoma and melanocytic naevus, but similarly in primary and metastatic melanomas. J Clin Pathol 2005; 58:1081-1085.
25. Vucic D, Franklin MC, Wallweber HJA, Das K, Eckelman BP, Shin H, et al. Engineering ML-IAP to produce an extraordinarily potent caspase 9 inhibitor: implications for Smac-dependent anti-apoptotic activity of ML-IAP. Biochem J 2005; 385:11-20.
26. Nachmias B, Ashhab Y, Bucholtz V, Drize O, Kadouri L, Lotem M, et al. Caspase-mediated cleavage converts Livin from an antiapoptotic to a proapoptotic factor: implications for drug-resistant melanoma. Caner Res 2003; 83:6340-6349.
27. Crnkovic-Mertens I, Semzow J, Hoppe-Seyler F, Butz K. Isoform-specific silencing of the Livin gene by RNA interference defines Livin beta as key mediator of apoptosis inhibition in HeLa cells. J Mol Med 2006; 84:232-240.
28. Crnkovic-Mertens I, Hoppe-Seyler F, Butz K. Induction of apoptosis in tumor cells by siRNA-mediated silencing of the livin/ML-IAP/KIAP gene. Oncogene 2003; 22:8330-8336.
29. Jansen B, Schlagbauer-wadl H, Brown BD, Bryan RN, van Elsas A, Muller M, et al. BCL-2 antisense therapy chemosensitizes human melanoma in SCID mice. Nat Med 1998; 4:232-234.
30. Jansen B, Wacheck V, Heere-Ress E, Schlagbauer-Wadl H, Hoeller C, Lucas T, et al. Chemosensitization of malignant melanoma By BCL-2 antisense therapy. Lancet 2000; 356:1728-1733.
31. L expression efficiently induces apoptosis in tumor cells. Clin Cancer Res 2000; 6:2547-2555.
32. L antisense treatment induces apoptosis in breast carcinoma cells. Int J Cancer 2000; 87:582-590.
33. Grossman D, Kim PJ, Scheohner JS, Altieri DC. Inhibition of melanoma tumor growth in vivo by survivin targeting. Proc Natl Acad Sci USA 2001; 98:635-640.
34. Li F, Ackermann EJ, Bennett CF, Rothermel AL, Plescia J, Tognin S, et al. Pleiotropic cell-division defects and apoptosis induced by interference with survivin function. Nat Cell Biol 1999; 1:461-466.
35. Olie RA, Simoes-Wust P, Baumann B, Leech SH, Fabbro D, Stahel RA, Zangemeister-Wittke U. A novel antisense oligonucleotide targeting survivin expression induces apoptosis and sensitizes lung cancer cells to chemotherapy. Cancer Res 2000; 60:2805-2809.
36. Hoeller C, Pratscher B, Thallinger C, Winter D, Fink D, Kovacic B, et al. Clusterin regulates drug-resistance in melanoma cells. J Invest Dermatol 2005; 124:1300-1307.
37. L antisense oligonucleotides induce apoptosis in melanoma cells of different clinical stages. J Invest Dermatol 2002; 118:505-512.
38. Yamashita T, Tokino T, Tonoki H, Moriuchi T, Jin H-Y, Omori F, et al. Induction of apoptosis in melanoma cell lines by p53 and its related proteins. J Invest Dermatol 2001; 117:914-919.
39. Matzura O, Wennborg A. RNAdraw: an integrated program for RNA secondary structure calculation and analysis under 32-bit Microsoft windows. Comput Appl Biosci 1996; 12:247-249.
40. Ziegler A, Simoes-Wust AP, Zangemeister-Wittke U. Optimizing efficacy of antisense oligodeoxynucleotides targeting inhibitors of apoptosis. Methods Enzymol 1999; 314:477-490.
41. Bradford MM. A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal Biochem 1976; 72:248-254.
42. Gazzaniga P, Gradilone A, Giuliani L, Gandini O, Silvestri I, Nofroni I, et al. Expression and prognostic significance of Livin, Survivin in superficial bladder cancer. Ann Oncol 2003; 14:85-90.
43. Tanabe H, Yagihashi A, Shijubo Y, Abe S, Watanabe N. Expression of survivin mRNA and livin mRNA in non-small-cell lung cancer. Lung cancer 2004; 46:299-304.
44. Wachwck V, Lasert D, Gunsberg P, Vornlocher HP, Hadwiger P, Gelch A. Small interfering RNA targeting bcl2 sensitizes malignant melanoma. Oligonucleotides 2003; 13:393-400.
45. Shibuya H, Kato Y, Saito M, Isobe T, Tsubi R, Koga M. Induction of apoptosis and/or necrosis following exposure to antitumor agents in a melanoma cell line, probably through modulation of Bcl2 family proteins. Melanoma Res 2003; 13:457-464.